logo
Plus   Neg
Share
Email

AZN : Late-stage Trial On Ovarian Cancer Fails To Meet Primary Endpoint Of PFS

AstraZeneca plc (AZN.L,AZN) and Merck & Co., in on update on phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer, said that the trial did not meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in progression-free survival or PFS with cediranib added to Lynparza versus platinum-based chemotherapy.

Cediranib is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor, which blocks the growth of blood vessels supporting tumour growth.

Jose´ Baselga, Executive Vice President, Oncology R&D, said, "Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT